Skip to content

Study · Randomized controlled trial · n = 1,605 · 2025

14 results

Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.

Linetzky B, Sattar N, Verma S, Krumholz HM, Xie CC, Hoffmann HT, Zimner-Rapuch S, Torcello-Gómez A, Stefanski A

Annals of internal medicine24 Jun 2025Cited by 10 (Europe PMC)

PMID40550133 (opens in a new tab)DOI10.7326/annals-24-02623 (opens in a new tab)PepBankPUB-40550133
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, the relationship between percentage weight reduction and waist circumference change seemed mostly linear.

    In plain wordsIn adults with obesity on tirzepatide, waist size fell in step with the amount of weight lost.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWaist circumference change by degree of weight reduction
    Study

    n = 1,605

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    The relationship between percentage weight reduction and changes in cardiometabolic risk factors seemed mostly linear for waist circumference and blood pressure, with a steeper slope for systolic than diastolic blood pressure.
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, systolic blood pressure change seemed mostly linear with weight reduction, with a steeper slope than diastolic blood pressure.

    In plain wordsIn adults with obesity on tirzepatide, systolic blood pressure fell in step with weight lost, more steeply than diastolic.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSystolic blood pressure change by degree of weight reduction
    Study

    n = 1,605

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    The relationship between percentage weight reduction and changes in cardiometabolic risk factors seemed mostly linear for waist circumference and blood pressure, with a steeper slope for systolic than diastolic blood pressure.
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, diastolic blood pressure change seemed mostly linear with weight reduction, with a shallower slope than systolic blood pressure.

    In plain wordsIn adults with obesity on tirzepatide, diastolic blood pressure fell in step with weight lost, less steeply than systolic.

    Peptide
    Tirzepatide
    Outcome
    DecreaseDiastolic blood pressure change by degree of weight reduction
    Study

    n = 1,605

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    The relationship between percentage weight reduction and changes in cardiometabolic risk factors seemed mostly linear for waist circumference and blood pressure, with a steeper slope for systolic than diastolic blood pressure.
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, HOMA-IR decreased even with modest weight reduction, with the steepest effect between less than 5% and less than 20% weight reduction.

    In plain wordsIn adults with obesity on tirzepatide, insulin resistance fell even with modest weight loss.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHOMA-IR decrease by degree of weight reduction
    Study

    n = 1,605

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Decreases in HOMA-IR and hemoglobin A1c were observed even with modest weight reduction, with the steepest effect occurring between less than 5% and less than 20% weight reduction.
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, hemoglobin A1c decreased even with modest weight reduction, with the steepest effect between less than 5% and less than 20% weight reduction.

    In plain wordsIn adults with obesity on tirzepatide, average blood sugar (HbA1c) fell even with modest weight loss.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHemoglobin A1c decrease by degree of weight reduction
    Study

    n = 1,605

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Decreases in HOMA-IR and hemoglobin A1c were observed even with modest weight reduction, with the steepest effect occurring between less than 5% and less than 20% weight reduction.
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, improvement in triglycerides was primarily seen only after weight reductions greater than 10%.

    In plain wordsIn adults with obesity on tirzepatide, triglycerides improved mainly after weight loss of more than 10%.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTriglyceride improvement by degree of weight reduction
    Study

    n = 1,605

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvements in levels of triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein cholesterol, and non-HDL cholesterol were primarily observed only after weight reductions greater than 10%.
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, improvement in HDL cholesterol was primarily seen only after weight reductions greater than 10%.

    In plain wordsIn adults with obesity on tirzepatide, HDL cholesterol improved mainly after weight loss of more than 10%.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHDL cholesterol improvement by degree of weight reduction
    Study

    n = 1,605

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvements in levels of triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein cholesterol, and non-HDL cholesterol were primarily observed only after weight reductions greater than 10%.
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, improvement in LDL cholesterol was primarily seen only after weight reductions greater than 10%.

    In plain wordsIn adults with obesity on tirzepatide, LDL cholesterol improved mainly after weight loss of more than 10%.

    Peptide
    Tirzepatide
    Outcome
    DecreaseLDL cholesterol improvement by degree of weight reduction
    Study

    n = 1,605

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvements in levels of triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein cholesterol, and non-HDL cholesterol were primarily observed only after weight reductions greater than 10%.
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, improvement in non-HDL cholesterol was primarily seen only after weight reductions greater than 10%.

    In plain wordsIn adults with obesity on tirzepatide, non-HDL cholesterol improved mainly after weight loss of more than 10%.

    Peptide
    Tirzepatide
    Outcome
    DecreaseNon-HDL cholesterol improvement by degree of weight reduction
    Study

    n = 1,605

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvements in levels of triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein cholesterol, and non-HDL cholesterol were primarily observed only after weight reductions greater than 10%.
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, those who lost at least 35% of body weight had systolic blood pressure changes of up to -14.2 mm Hg from baseline to week 72.

    In plain wordsIn adults with obesity on tirzepatide, those who lost at least 35% of body weight had lower systolic blood pressure at week 72.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSystolic blood pressure change at week 72 with weight reduction of at least 35%
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Measurements

    Systolic blood pressure change
    −14.2 mm Hg
    weight reduction of at least 35%, week 72

    Source sentences

    Summary
    Participants who lost at least 35% of their body weight from baseline to week 72 had mean changes of up to -14.2 mm Hg (95% CI, -16.1 to -12.3 mm Hg) for systolic blood pressure
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, those who lost at least 35% of body weight had diastolic blood pressure changes of up to -9.2 mm Hg from baseline to week 72.

    In plain wordsIn adults with obesity on tirzepatide, those who lost at least 35% of body weight had lower diastolic blood pressure at week 72.

    Peptide
    Tirzepatide
    Outcome
    DecreaseDiastolic blood pressure change at week 72 with weight reduction of at least 35%
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Measurements

    Diastolic blood pressure change
    −9.2 mm Hg
    weight reduction of at least 35%, week 72

    Source sentences

    Summary
    -9.2 mm Hg (CI, -10.6 to -7.8 mm Hg) for diastolic blood pressure
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, those who lost at least 35% of body weight had waist circumference changes of up to -32.4 cm from baseline to week 72.

    In plain wordsIn adults with obesity on tirzepatide, those who lost at least 35% of body weight had a much smaller waist at week 72.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWaist circumference change at week 72 with weight reduction of at least 35%
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Measurements

    Waist circumference change
    −32.4 cm
    weight reduction of at least 35%, week 72

    Source sentences

    Summary
    -32.4 cm (CI, -33.5 to -31.3 cm) for waist circumference
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.
  13. 13HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, those who lost at least 35% of body weight had HOMA-IR changes of up to -59.7% from baseline to week 72.

    In plain wordsIn adults with obesity on tirzepatide, those who lost at least 35% of body weight had much lower insulin resistance at week 72.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHOMA-IR change at week 72 with weight reduction of at least 35%
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Measurements

    HOMA-IR change
    −59.7%
    weight reduction of at least 35%, week 72

    Source sentences

    Summary
    -59.7% (CI, -63.6% to -55.3%) for the homeostatic model assessment of insulin resistance (HOMA-IR)
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.
  14. 14HumanRandomized controlled trialEfficacy outcome

    In adults with obesity treated with tirzepatide, those who lost at least 35% of body weight had hemoglobin A1c changes of up to -0.65 percentage point from baseline to week 72.

    In plain wordsIn adults with obesity on tirzepatide, those who lost at least 35% of body weight had lower average blood sugar (HbA1c) at week 72.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change at week 72 with weight reduction of at least 35%
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    5, 10 or 15 mg · 72 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.65 percentage point
    weight reduction of at least 35%, week 72

    Source sentences

    Summary
    -0.65 percentage point (CI, -0.70 to -0.61 percentage point) for hemoglobin A1c.
    2 context sentences
    Summary · context
    Adults (n = 1605) with obesity, or overweight with weight-related complications (excluding diabetes), randomly assigned to tirzepatide treatment groups.
    Summary · context
    Once-weekly tirzepatide, 5, 10, or 15 mg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04184622

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Eli Lilly and Companyn = 2,5394 Dec 2019 to 6 Jul 2024

Overweight · Obesity

Trial pageClinicalTrials.govUpdated 24 Jul 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.